Payment overview · 2025
General Payments
$266.18
16 reported records · 5 companies
Healthcare provider profile · identity verified
Martin L. Codispoti, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LOGAN, WV · NPI 1265717250
Verified facts
What the public records show
CMS Open Payments records show Martin L. Codispoti, FNP-BC received $266.18 in general payments during 2025 across 16 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 53.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ozempic, Trulance.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $141.37 | 53.1% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.68 | 23.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.84 | 9.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.74 | 7.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.55 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $266.18 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $126.84 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.68 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $63.68 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 425 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 321 | 75 |
| Alprazolam | Alprazolam | 296 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 260 | 75 |
| Lisinopril | Lisinopril | 213 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 199 | 53 |
| Potassium Chloride | Potassium Chloride | 192 | 45 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 188 | 35 |
| Montelukast Sodium | Montelukast Sodium | 188 | 45 |
| Omeprazole | Omeprazole | 182 | 47 |
| Furosemide | Furosemide | 177 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 44 |
| Losartan Potassium | Losartan Potassium | 157 | 40 |
| Pregabalin | Pregabalin | 157 | 25 |
| Ibuprofen | Ibuprofen | 155 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 152 | 26 |
| Clonazepam | Clonazepam | 143 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 121 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 40 |
| Meloxicam | Meloxicam | 111 | 32 |
| Metformin Hcl Er | Metformin Hcl | 107 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 25 |
| Cephalexin | Cephalexin | 98 | 71 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 27 |
| Methylprednisolone | Methylprednisolone | 98 | 69 |
| Metformin Hcl | Metformin Hcl | 95 | 27 |
| Tramadol Hcl | Tramadol Hcl | 94 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 15 |
| Prednisone | Prednisone | 93 | 47 |
| Famotidine | Famotidine | 90 | 30 |
| Ondansetron Odt | Ondansetron | 88 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 28 |
| Sertraline Hcl | Sertraline Hcl | 83 | 13 |
| Farxiga | Dapagliflozin Propanediol | 78 | 23 |
| Lorazepam | Lorazepam | 77 | 15 |
| Bupropion Xl | Bupropion Hcl | 75 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 16 |
| Ozempic | Semaglutide | 69 | 20 |
| Jardiance | Empagliflozin | 67 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | suppressed |
| Fenofibrate | Fenofibrate | 56 | 12 |
| Fluconazole | Fluconazole | 53 | 26 |
| Azithromycin | Azithromycin | 52 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 15 |
| Tradjenta | Linagliptin | 51 | 14 |
| Diazepam | Diazepam | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 11 |
| Promethazine Hcl | Promethazine Hcl | 46 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 17 |
| Torsemide | Torsemide | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 13 |
| Mounjaro | Tirzepatide | 42 | 11 |
| Sucralfate | Sucralfate | 41 | 13 |
| Eliquis | Apixaban | 40 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 14 |
| Mirtazapine | Mirtazapine | 39 | 11 |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Simvastatin | Simvastatin | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | 11 |
| Nitroglycerin | Nitroglycerin | 36 | 14 |
| Carvedilol | Carvedilol | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 12 |
| Vascepa | Icosapent Ethyl | 33 | 11 |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 13 |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Amoxicillin | Amoxicillin | 28 | 17 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 11 |
| Linzess | Linaclotide | 25 | suppressed |
| Nystatin | Nystatin | 25 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 14 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Trulance | Plecanatide | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $266.18 · 16 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | CAPLYTA, Cologuard Collection Kit, NURTEC ODT, Ozempic, TRULANCE, XIFAXAN, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error